These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 29052527)

  • 1. Negative genic switch of HER-2 in the primary tumor instead of the synchronous metastatic nodal lesions after neoadjuvant chemotherapy in a patient with primary HER2-positive breast cancer.
    Chen HR; Wu YT; Yu QB; Yang YY; Wei YX; Li HY; Wu KN; Kong LQ
    World J Surg Oncol; 2017 Oct; 15(1):189. PubMed ID: 29052527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study.
    Zhang Y; Mo M; Li JW; Zhou Y; Wu J; Yu KD; Shen ZZ; Shao ZM; Liu GY
    Eur J Surg Oncol; 2016 Aug; 42(8):1146-52. PubMed ID: 27365197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease.
    Al-Hilli Z; Hieken TJ; Hoskin TL; Heins CN; Boughey JC
    J Surg Oncol; 2015 Oct; 112(5):453-7. PubMed ID: 26345596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.
    Enokido K; Watanabe C; Nakamura S; Ogiya A; Osako T; Akiyama F; Yoshimura A; Iwata H; Ohno S; Kojima Y; Tsugawa K; Motomura K; Hayashi N; Yamauchi H; Sato N
    Clin Breast Cancer; 2016 Aug; 16(4):299-304. PubMed ID: 26993216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
    Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic Complete Response in HER2-Positive Breast Cancer Patients Receiving Trastuzumab in Neoadjuvant Setting.
    Sheikh F; Nazir A; Yasmeen S; Badar F; Ahmad U; Siddiqui N
    J Coll Physicians Surg Pak; 2019 Feb; 29(2):159-163. PubMed ID: 30700356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery.
    Tadros AB; Yang WT; Krishnamurthy S; Rauch GM; Smith BD; Valero V; Black DM; Lucci A; Caudle AS; DeSnyder SM; Teshome M; Barcenas CH; Miggins M; Adrada BE; Moseley T; Hwang RF; Hunt KK; Kuerer HM
    JAMA Surg; 2017 Jul; 152(7):665-670. PubMed ID: 28423171
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer.
    Hergueta-Redondo M; Sarrio D; Molina-Crespo Á; Vicario R; Bernadó-Morales C; Martínez L; Rojo-Sebastián A; Serra-Musach J; Mota A; Martínez-Ramírez Á; Castilla MÁ; González-Martin A; Pernas S; Cano A; Cortes J; Nuciforo PG; Peg V; Palacios J; Pujana MÁ; Arribas J; Moreno-Bueno G
    Oncotarget; 2016 Aug; 7(35):56295-56308. PubMed ID: 27462779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparison of HER2 gene status between primary breast cancer and synchronous axillary lymph node metastasis].
    Liu YY; Wu SF; Liang ZY; Zeng X
    Zhonghua Bing Li Xue Za Zhi; 2016 Jun; 45(6):393-6. PubMed ID: 27256047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women.
    Fowble B; Jairam AK; Wang F; Peled A; Alvarado M; Ewing C; Esserman L; Park C; Lazar A
    Clin Breast Cancer; 2018 Feb; 18(1):e107-e113. PubMed ID: 28830795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer.
    Curigliano G; Criscitiello C
    J Clin Oncol; 2017 Aug; 35(23):2600-2603. PubMed ID: 28661760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer.
    Stoen E; Kabos P; Borden KC; Brown RJ; Borges VF; Diamond JR
    Oncology (Williston Park); 2018 Jun; 32(6):298-302. PubMed ID: 29940061
    [No Abstract]   [Full Text] [Related]  

  • 13. Concordance Between FISH Analysis of Her-2/Neu Gene in Breast Duct Carcinoma and Corresponding Axillary Nodal Metastases: Egyptian National Cancer Institute Experience.
    Badawy OM; Hassan H; ELBakey HA; Mosaad M
    Appl Immunohistochem Mol Morphol; 2019 Apr; 27(4):295-300. PubMed ID: 29750667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker conversion from primary breast cancer to synchronous axillary lymph node metastasis and neoadjuvant therapy response: a single-center analysis.
    Ding M; Li M; Liu Q; Xu L
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):297. PubMed ID: 38850362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Rare Case of S310F Somatic ERBB2 Mutation in a HER2-Nonamplified Breast Cancer.
    Jasra S; Opyrchal M; Norton L; Mehta R
    Clin Breast Cancer; 2017 Feb; 17(1):e37-e41. PubMed ID: 27665021
    [No Abstract]   [Full Text] [Related]  

  • 16. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype.
    Namura M; Tsunoda H; Yagata H; Hayashi N; Yoshida A; Morishita E; Takei J; Suzuki K; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):128-134. PubMed ID: 28843513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2-positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy.
    Calhoun BC; Portier B; Wang Z; Minca EC; Budd GT; Lanigan C; Tubbs RR; Morrison LE
    BMC Cancer; 2016 Aug; 16(1):695. PubMed ID: 27576528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of HER2 Immunohistochemistry-Negative, FISH-Amplified Breast Cancers and Their Response to Anti-HER2 Neoadjuvant Chemotherapy.
    Gibbons-Fideler IS; Nitta H; Murillo A; Tozbikian G; Banks P; Parwani AV; Li Z
    Am J Clin Pathol; 2019 Jan; 151(2):176-184. PubMed ID: 30339245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.